Relacorilant
Brand names: Lifyorli · Active ingredient: Relacorilant
In short: LIFYORLI is indicated in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab .
What is Relacorilant used for?
LIFYORLI is indicated in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab .
Relacorilant dosage
LIFYORLI
Follow LIFYORLI dosing instructions provided on the blister card.
Take LIFYORLI with food.
Swallow capsules whole. Do not crush, chew, dissolve, or split the capsules.
If a dose of LIFYORLI is missed by less than 12 hours, take the missed dose. If a dose of LIFYORLI is missed by 12 hours or more, skip the missed dose and take the next dose at the regularly scheduled time. Do not take 2 doses at the same time to make up for a missed dose.
If vomiting occurs after taking LIFYORLI, do not take an additional dose.
Nab-Paclitaxel
The recommended dosage and dosage modifications for nab-paclitaxel when administered in combination with LIFYORLI differ from those for other nab-paclitaxel indications .
Do not substitute with other paclitaxel formulations.
The recommended dosage of LIFYORLI is 150 mg orally once on the day before, the day of, and the day after each nab-paclitaxel infusion until disease progression or unacceptable toxicity.
The recommended dosage for nab-paclitaxel is 80 mg/m2 administered as an intravenous infusion on Days 1, 8 and 15 of each 28-day cycle until disease progression or unacceptable toxicity . Refer to the Prescribing Information for nab-paclitaxel for administration.
Dose reduction levels are summarized in Table 1 and Table 2.
Dose Reduction | Nab-Paclitaxel
First | 60 mg/m2 on Days 1, 8 and 15 of each 28-day cycle
Second | 60 mg/m2 on Days 1 and 15 ofeach 28-day cycle
Third | Permanently discontinue nab-paclitaxel if unable to tolerate after two dose reductions.
Dose Reduction | LIFYORLI
First | 125 mg once the day before, the day of and the day after the nab-paclitaxel infusion
Second | Permanently discontinue LIFYORLI in patients unable to tolerate after one dose reduction.
The recommended dosage modifications for adverse reactions are provided in Tables 3 and 4. Interrupt or discontinue LIFYORLI whenever nab-paclitaxel is interrupted or discontinued.
Adverse Reaction | Severity
a | Dosage Modification
a Unless otherwise specified, Grade per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0.
b Supportive short acting G-CSF administered 24 hours after nab-paclitaxel for 2 days in accordance with clinical practice.
c If the delay in nab-paclitaxel dosing exceeds 7 days, omit the nab-paclitaxel dose. …
How to take Relacorilant — instructions & advice from the label
Advise patients to read the FDA-approved patient labeling (Patient Information).
Neutropenia and Severe Infections
Inform patients about the risk of neutropenia and infection. Instruct patients to immediately report any fever or symptoms of infection to their healthcare provider .
Adrenal Insufficiency
Inform patients that LIFYORLI can cause adrenal insufficiency, a potentially life-threatening condition. Advise patients to immediately report signs or symptoms of adrenal insufficiency to their healthcare provider .
Exacerbation of Conditions Treated with Glucocorticoids
Advise patients who require chronic or frequent use of glucocorticoids that glucocorticoids may be less effective and to contact their healthcare provider for any worsening symptoms during concomitant use .
Embryo-Fetal Toxicity
Advise pregnant women and females of reproductive potential of the potential risk to a fetus.
Advise females to inform their healthcare provider of a known or suspected pregnancy. Advise females of reproductive potential to use effective contraception during treatment with LIFYORLI and for 1 week after the last dose. …
Warnings & precautions
Do not take this medicine if: LIFYORLI is contraindicated in patients receiving systemic glucocorticoids for lifesaving purposes (e.g., immunosuppression after organ transplantation) because LIFYORLI antagonizes the effect of glucocorticoids .
LIFYORLI in combination with nab-paclitaxel can cause neutropenia, including febrile neutropenia and severe infections.
In ROSELLA, decreased neutrophil count occurred in 74% of patients treated with LIFYORLI in combination with nab-paclitaxel, 30% Grade 3, 15% Grade 4, and 3.7% febrile neutropenia. The median time to onset of neutropenia was 15 days (range: 8 to 329). Instances of neutropenia were temporally associated with infection in 16% of patients. There was one fatal event of septic shock with febrile neutropenia. Thirty-eight percent of patients initiated granulocyte colony-stimulating factor (G-CSF) during the first or second cycle of therapy.
Monitor complete blood counts prior to each weekly treatment with LIFYORLI in combination with nab-paclitaxel and as clinically indicated. Based on the severity of neutropenia, delay, reduce dose or permanently discontinue LIFYORLI in combination with nab-paclitaxel. Consider short-acting G-CSF administration as applicable . Consider the possibility of concurrent adrenal insufficiency, particularly in the setting of serious infection . Inform patients to promptly report any episodes of fever to their healthcare provider.
LIFYORLI is a reversible glucocorticoid receptor antagonist and can cause adrenal insufficiency. Adrenal insufficiency can occur at any time during treatment with LIFYORLI. The risk of adrenal insufficiency is increased in situations of stress, such as acute illness, infection, or surgery. Consider whether supplemental glucocorticoids are required in the perioperative period in patients who have received LIFYORLI within 30 days of surgery. …
Relacorilant side effects
The following adverse reactions are discussed in more detail in other sections of the labeling:
Neutropenia and Severe Infections .
Adrenal Insufficiency
Exacerbation of Conditions Treated with Glucocorticoids .
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of LIFYORLI in combination with nab-paclitaxel was evaluated in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer in ROSELLA .
Patients received LIFYORLI (150 mg orally on the day before, the day of, and the day after each administration of nab-paclitaxel 80 mg/m2 intravenous infusion on Days 1, 8 and 15 of each 28-day cycle (n=188) or nab-paclitaxel 100 mg/m2 intravenous infusion (n=190) until disease progression or unacceptable toxicity. LIFYORLI dosing was interrupted whenever nab-paclitaxel was interrupted. The median duration of LIFYORLI treatment was 4.7 months (range: 0.2 to 24).
Serious adverse reactions occurred in 35% of patients who received LIFYORLI in combination with nab-paclitaxel. Serious adverse reactions in ≥2% of patients were neutropenia (4%), pneumonia (3.2%), pleural effusion (3.2%), febrile neutropenia (2.1%), and fatigue (2.1%). …
Drug interactions
Strong CYP3A Inducers
Avoid coadministration of LIFYORLI plus nab-paclitaxel with strong CYP3A inducers.
Both relacorilant and paclitaxel are CYP3A substrates. Coadministration of strong CYP3A inducers can decrease concentrations of relacorilant and paclitaxel, which may reduce their effectiveness .
CYP2C8 Inducers and Moderate CYP3A Inducers
Monitor for reduced effectiveness of LIFYORLI plus nab-paclitaxel with CYP2C8 inducers and moderate CYP3A inducers.
Paclitaxel is a substrate of CYP2C8 and CYP3A and relacorilant is a CYP3A substrate. Coadministration of CYP2C8 inducers and moderate CYP3A inducers can decrease concentrations of paclitaxel and relacorilant, which may reduce their effectiveness.
CYP2C8 Inhibitors
Monitor for increased adverse reactions and modify the dosage for adverse reactions as recommended .
Paclitaxel is a substrate of CYP2C8. Coadministration of CYP2C8 inhibitors may increase concentrations of paclitaxel, which may increase the risk of adverse reactions.
CYP3A Substrates
Avoid concomitant use unless otherwise recommended in the Prescribing Information for CYP3A substrates.
Relacorilant is a strong CYP3A inhibitor. Relacorilant increases exposure of CYP3A substrates , which may increase the risk for adverse reactions related to these substrates. …
About this medicine
LIFYORLI (relacorilant) is a glucocorticoid receptor antagonist antineoplastic agent.
Relacorilant chemical names:
(R)-(1-(4-fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-trifluoromethyl)(pyridin-2-yl)methanone
[(4aR)-1-(4-fluorophenyl)-6-(1-methyl-1H-pyrazole-4-sulfonyl)-1,4,5,6,7,8-hexahydro-4aH-pyrazolo[3,4-g]isoquinolin-4a-yl][4-(trifluoromethyl)pyridin-2-yl]methanone
The molecular formula is C27H22F4N6O3S and the molecular weight is 586.57 g/mol. The chemical structure of relacorilant is:
Relacorilant is an off-white to light yellow solid that is practically insoluble in aqueous media.
LIFYORLI capsules for oral use are supplied as immediate release, printed, soft gelatin capsules containing 25 mg or 100 mg of relacorilant. Each capsule contains the following excipients: butylated hydroxytoluene, lauroyl polyoxyl-32 glycerides, and propylene glycol caprylate. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 6fcebfb5-19d6-4f63-b852-999d68a13729. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate